Law360, New York (February 26, 2010, 6:08 PM ET) -- Watson Laboratories Inc. has filed a declaratory judgment suit against Teva Women’s Health Inc., seeking a ruling that its bid to make a generic version of oral contraceptive Seasonique does not infringe a separate patent covering a lower dosage of the drug.
The generics maker filed its complaint Thursday in the U.S. District Court for the District of Nevada, disputing the validity of a “nearly identical” patent assigned to the Teva unit, formerly known as Duramed Pharmaceuticals Inc.
Watson brought the suit to “avoid legal uncertainty...
Watson Targets Teva's Patent For LoSeasonique
To view the full article, take a free trial now.
